The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
News|Videos|December 12, 2025
IMvigor011: A Phase 3 Trial of Circulating Tumour (ct)DNA-Guided Adjuvant Atezolizumab vs Placebo in Muscle-Invasive Bladder Cancer
Author(s)Thomas Powles MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MD discusses IMvigor011: a Phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer.
Advertisement
Thomas Powles, MBBS, MRCP, MD discusses how, his study reports that in the phase 3 IMvigor011 trial, ctDNA-positive patients with muscle-invasive bladder cancer who received adjuvant atezolizumab had statistically significant improvements in both disease-free survival and overall survival compared with placebo. The results support using serial ctDNA monitoring to identify patients who benefit from immunotherapy while safely sparing persistently ctDNA-negative patients from unnecessary treatment.
Advertisement
Related to this article
Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Advertisement
Advertisement
Trending on OncLive
1
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
2
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
3
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
4
FDA Grants Breakthrough Device Designation to Merlin CP-GEP for Early-Stage Melanoma Risk Stratification
5